Macrogenics Stock News

Wall Street analysts expect that MacroGenics, Inc. (NASDAQ:MGNX) will announce ($0.83) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for MacroGenics earnings, with the highest EPS estimate coming in at ($0.71) and the lowest estimate coming in at ($1.00). MacroGenics posted earnings of $0.02 per share during []

Shares of MacroGenics, Inc. (NASDAQ:MGNX) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $17.13 and last traded at $17.25, with a volume of 7222 shares changing hands. The stock had previously closed at $17.91. A number of equities research analysts have recently issued reports on MGNX []

Analysts predict that MacroGenics, Inc. (NASDAQ:MGNX) will announce earnings per share (EPS) of ($0.83) for the current quarter, according to Zacks. Four analysts have made estimates for MacroGenics earnings, with estimates ranging from ($1.00) to ($0.71). MacroGenics posted earnings per share of $0.02 in the same quarter last year, which would indicate a negative year-over-year []

Metropolitan Life Insurance Co NY lifted its position in MacroGenics, Inc. (NASDAQ:MGNX) by 107,513.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,142 shares of the biopharmaceutical companys stock after acquiring an additional 16,127 shares during the quarter. Metropolitan Life []

Shares of MacroGenics, Inc. (NASDAQ:MGNX) have received a consensus recommendation of Buy from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The []

AQR Capital Management LLC cut its holdings in MacroGenics, Inc. (NASDAQ:MGNX) by 23.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 42,394 shares of the biopharmaceutical companys stock after selling 12,972 shares during the period. AQR Capital Management LLC owned 0.07% []

MacroGenics, Inc. (NASDAQ:MGNX) has earned a consensus rating of “Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 12-month price objective among […]

Los Angeles, USA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Promising Treatment for Advanced Hepatocellular Carcinoma Enters Clinical Trials | DelveInsight There are a plethora of companies developing therapies to treat Advanced Hepatocellular Carcinoma. CStone Pharmaceuticals has its drug candidate in the most advanced stage (Phase III). DelveInsight''s " Advanced Hepatocellular Carcinoma Pipeline Insight " report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Advanced Hepatocellular Carcinoma pipeline landscapes. It comprises Advanced Hepatocellular Carcinoma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Advanced Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Advanced Hepatocellular Carcinoma pipeline products. Some of the key takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report Major companies such as CStone Pharmaceuticals, Akesobio, Chia Tai Tianqing Pharmaceutical Group, Yiviva Inc., BeiGene, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Carsgen Therapeutics, Ltd., Jiangsu Alphamab Biopharmaceuticals, Sunshine Lake Pharma Co., Ltd., AVEO Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd., Sinocelltech Ltd., LTD, Eureka Therapeutics Inc., Taizhou Hanzhong biomedical co.

MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q3 2021 Results - Earnings Call Transcript

MacroGenics (MGNX) delivered earnings and revenue surprises of -36.51% and -60.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeuti

MacroGenics Inc (NASDAQ: MGNX) announced preliminary safety and anti-tumor activity data from dose-expansion cohorts of the Phase 1 trial of MGC018. The data was presented at the 2021 European Soci

Investors weren't thrilled with the company's latest clinical data.

ROCKVILLE, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeut

ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeut